Synovus Financial Corp Has $2.48 Million Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Synovus Financial Corp cut its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 37.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,601 shares of the medical equipment provider’s stock after selling 13,347 shares during the period. Synovus Financial Corp’s holdings in Lantheus were worth $2,481,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB acquired a new stake in Lantheus in the third quarter valued at approximately $25,000. Signaturefd LLC grew its position in Lantheus by 40.5% in the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 92 shares during the period. Nkcfo LLC bought a new stake in Lantheus during the 2nd quarter valued at $47,000. UMB Bank n.a. increased its stake in Lantheus by 42.1% during the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after purchasing an additional 126 shares in the last quarter. Finally, Kathleen S. Wright Associates Inc. acquired a new position in Lantheus during the third quarter worth $51,000. 99.06% of the stock is owned by institutional investors.

Lantheus Stock Up 1.2 %

LNTH stock opened at $93.02 on Monday. The business has a 50 day moving average of $97.88 and a 200-day moving average of $98.11. The firm has a market cap of $6.47 billion, a PE ratio of 15.48 and a beta of 0.45. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $126.89.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Truist Financial reiterated a “buy” rating and set a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. JMP Securities decreased their price objective on Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a report on Thursday, November 7th. Finally, Redburn Atlantic began coverage on Lantheus in a report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 target price on the stock. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $130.00.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.